In a recently published study from the Hallym University College of Medicine, researchers have applied mesenchymal stem cells [MSCs] to animal models afflicted with global cerebral ischemia [GCI] to successfully reduce the associated neuronal damage. When compared to those that received no treatment, animals that received MSCs displayed a significant decrease in cell death, inflammation to the brain, and disruption of the blood brain barrier. Continue reading
Mesenchymal stem cells (MSCs) are a type of adult stem cell that can be expanded in-vitro [outside the body] and differentiated into a multitude of tissue types; such as bone, muscle, connective tissue, neurons, and insulin producing pancreatic beta cells. This is often referred to as ‘multipotency’. Because of the unique properties of MSCs, researchers from around the globe are utilizing them in the development of treatments and regenerative therapies to address a wide variety of disease, trauma and injury. For this reason, mesenchymal stem cell research is the fastest growing area of stem cell research.
In a pre-clinical trial, Researchers at the National University of Ireland Galway have found that mesenchymal stem cells (MSCs) demonstrate the ability to increase wound healing for diabetics’ related wounds. Diabetic patients have impaired ability to heal wounds with 25% of diabetic patients affected by foot ulcers; which may result in amputation.